bioAffinity's CyPath Lung Test Takes Center Stage at Cleveland Clinic Symposium
Event summary
- bioAffinity's CyPath Lung test will be featured at the Cleveland Clinic's annual lung cancer symposium on April 16, 2026.
- Gordon Downie, MD, PhD, bioAffinity's Chief Medical Officer, will join a panel discussing lung nodule management.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules.
- The test uses flow cytometry and AI to analyze sputum samples for cancer and cancer-related cells.
The big picture
bioAffinity's participation in the Cleveland Clinic symposium underscores the growing emphasis on early lung cancer detection and the role of noninvasive diagnostics. As the number of indeterminate pulmonary nodules discovered through screening increases, the demand for scalable, cost-effective solutions like CyPath Lung is likely to rise. The company's focus on AI-driven diagnostics positions it at the forefront of a broader industry shift toward precision medicine and data-driven healthcare.
What we're watching
- Market Adoption
- How bioAffinity will leverage the symposium to accelerate CyPath Lung's market penetration among high-risk patient populations.
- Regulatory Dynamics
- Whether the evolving regulatory landscape for Laboratory Developed Tests will impact CyPath Lung's commercialization strategy.
- Competitive Positioning
- The pace at which bioAffinity can differentiate CyPath Lung in a growing field of emerging diagnostic technologies for lung cancer.
Related topics